Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

Overview of attention for article published in New England Journal of Medicine, August 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 12 news outlets
blogs: 2 blogs
twitter: 266 X users
patent: 1 patent
facebook: 12 Facebook pages
wikipedia: 3 Wikipedia pages

googleplus: 3 Google+ users
reddit: 3 Redditors
f1000: 1 research highlight platform
guideline: 5 clinical guideline sources
bluesky: 2 Bluesky users

Readers on

mendeley: 571 Mendeley
citeulike: 2 CiteULike

So far, Altmetric has seen 2 Bluesky posts from 2 Bluesky users, with an upper bound of 2,407 followers.

RP @fipco.bsky.social: Not much separation in REVEAL till >2y. ACCELERATE stopped at ~2y. Also slight bp⬆️. Lipid/lipoprotein lowering with anacetrapib was atypical: direct LDL-C 41%⬇️, while BQ-LDL-C, non-HDL-C, and apoB more modest. REVEAL in line w CTT…

Not much separation in REVEAL till >2y. ACCELERATE stopped at ~2y. Also slight bp⬆️. Lipid/lipoprotein lowering with anacetrapib was atypical: direct LDL-C 41%⬇️, while BQ-LDL-C, non-HDL-C, and apoB more modest. REVEAL in line w CTT line on absolute non-H…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.